Genpact Limited (G) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Genpact Limited stock $61.02, price $42.27, upside +44.4%, quality 71 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
The stock costs 31% less than our calculation considers fair.
Fair value $61.02 · Undervalued
Quality 71/100
Solidly profitable · 11.0% net margin (TTM)
Low debt
Generates free cash flow
0.4% dividend yield · Well covered
Ranks above peers(11/15)
Wide moat68/100
Upbeat coverage
Broad data
Even on cautious assumptions the value is 5% above the price ($44.40).
Mixed Growth(revenue 5y +6.5 %/yr in USD)
Insiders sold $2.3M (6M)
Risks from the AI analysis
🚩Pure AI platforms could replace managed services🚩Higher-cost debt refinancing could squeeze margins🚩FEMA investigation could lead to penalties or asset issues
Watch Genpact Limited for free: we tell you when fair value or trend changes.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range $27.35 – $53.84 · fair‑value band $44.40 – $77.63 · the $42.27 price screens below the $61.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Genpact in your weekly email
Every Wednesday you see whether Genpact is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Genpact Limited provides business process outsourcing and information technology services in India, the rest of Asia, North and Latin America, and Europe. It operates through three segments: Financial services; Consumer and Healthcare; and High Tech and Manufacturing.
Show moreShow less
The Financial Services segment offers customer onboarding, customer service, collections, retail and commercial loan operations, payment operations, mortgage origination and servicing, compliance, wealth management, capital market operations support, financial crime and risk management, proprietary insurance policy suite, underwriting support, new business processing, policy administration, customer, claims management, catastrophe and exposure/risk modeling, actuarial services, end-to-end third-party administration for property and casualty claims, and technology services.
The Consumer and Healthcare segment provides demand generation, sensing and planning, supply chain planning and management, pricing and trade promotion management, deduction recovery management, order management, digital commerce, customer experience, lifecycle management, regulatory operations, chemistry manufacturing control compliance, regulatory information management, claims processing and adjudication, claims recovery and payment integrity, revenue cycle management, health equity analytics, and care services.
The High Tech and Manufacturing segment offers solutions for trust and safety, advertising sales support, customer and user experience, customer care support, supply chain management, direct and indirect procurement, logistics, field, aftermarket support, and engineering services.
It offers digital operations, data-tech-AI, advisory, agent technology; enterprise functional services, such as finance and accounting, human resources, sales and commercial operations, marketing, and global business solutions. The company has strategic alliance with Google Cloud.
The company was founded in 1997 and is based in Hamilton, Bermuda.
Stock analysis
Genpact Limited (G) currently trades at $42.27, while our model-based Fair Value estimate is $61.02, implying the stock looks roughly 31% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $82.30 per share, and 18 of the 26 models we run sit above the $42.27 price.
Bear case: the Dividend Discount group reads lowest at $13.22, and 8 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: $44.40 (bear) to $77.63 (bull), the price of $42.27 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Technology sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Genpact Limited reported revenue of $5.1B in FY2025 versus $4.0B in FY2021, a compound +6.0%/yr. Reported net income was $552M in FY2025, compounding +10.6%/yr from FY2021.
Key figures
Market cap $7.2B Mid · P/E ratio 12.3 · P/S ratio 1.35 · EPS (TTM) $3.43 · Dividend yield 0.4% · Net margin 11.0% · Return on equity 22.4% · Return on assets (EBIT) 12.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 68 out of 100 (medium confidence).
What moves the price
The share trades about 11% below its 52-week high and 55% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Technology peers we cover trades at 20% fair-value upside, at 44%, G screens cheaper than that median.
Fair Value models
Bear$44.40Fair Value $61.02Bull$77.63
Price $42.27 · Upside +44.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($2.80 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
SaleTamara FranklinDirector2,750 shares at $45.65$125,538Nov 12, 2025
Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.74/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+6.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
Start year 2020 (pandemic). Over 10 years: +7.5% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+13.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+13.2%
Dividend (yield on the price)0.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.14.7% vs 11.1%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 15%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−5.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −7.3% a year for the price and +3.8% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: The business quality rests on a moderate moat from organization capital and pricing power in IT services, yet it remains constrained by average human capital and weak insider signals.
Main risk: Pure AI document and workflow platforms could substitute Genpact's multi-year managed services contracts with faster, lower-overhead subscriptions, hitting its core process services revenue and margins.
Bull case: Genpact could leverage its decades of process intelligence and domain expertise to embed superior agentic AI solutions into client workflows, expanding its addressable market and achieving higher-margin outcome-based revenue.
Bear case: If pure AI platforms or rivals erode its managed services faster than agentic offerings scale and higher debt costs compound the pressure, Genpact's core revenue streams could shrink materially while margins compress.
Genpact is pivoting hard toward agentic AI and outcome-based contracts that replace traditional headcount billing. The move promises higher margins in its technology solutions but risks disrupting the steady flow from its core process services. Will the shift expand its addressable market faster than it erodes existing revenue streams?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Information Technology Services · 479 stocks
Beats the industry median on 11/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score71 · Top 25%
Fair Value upside+44.4% · Above median
Profitability
Return on equity (12 months)22.4% · Top 25%
Return on assets9.5% · Top 25%
Net margin (12 months)11.0% · Top 25%
Operating margin (12 months)15.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)7.3% · Above median
Dividend yield (12 months)0.4% · Bottom 25%
Balance sheet
Debt / equity0.47× · Highest 25%
Valuation Multiplesvs Information Technology Services median · lower = cheaper
P/E (12 months)12.3× · Cheapest 25%
P/B2.83× · Pricier than median
P/S (12 months)1.35× · Pricier than median
Price / free cash flow (fiscal year)9.8× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Genpact Limited Fair Value". https://www.fairvalue-calculator.com/stock/G
Frequently asked questions
Is Genpact Limited (G) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $61.02 versus a price of $42.27, about +44% upside (undervalued).
What is the fair value of G?
Our model-based fair value for Genpact Limited is $61.02 (as of Nov 7, 2026), built from audited fundamentals. The current price: $42.27.
What is the quality score of G?
Genpact Limited has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genpact Limited (G)?
Our model-based price target is the fair value of $61.02 (as of Nov 7, 2026) from 26 valuation models. Cautious scenario $44.40, optimistic scenario $77.63. It is a calculation from audited fundamentals, not an analyst target.
What is the Genpact Limited stock forecast for 2026?
Our models put fair value at $61.02, about +44% upside versus a price of $42.27 (undervalued). Cautious scenario $44.40, optimistic scenario $77.63. The calculation is refreshed regularly with new filings.
What is the revenue of Genpact Limited (G)?
Genpact Limited reported trailing-twelve-month revenue of about $5.3B (latest available figure, as of Nov 7, 2026).
Does Genpact Limited pay a dividend?
Genpact Limited currently shows a dividend yield of 0.40% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Genpact Limited (G) and when is the ex-dividend date?
Genpact Limited pays a dividend of $0.17 per share a year, a dividend yield of 0.4%. The next ex-dividend date is Dec 10, 2026, with payment on Dec 23, 2026. A dividend has been paid every year since 2017. The payout ratio is 5.0% of earnings. Free cash flow covers the dividend 25.84 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Genpact Limited (G)?
For today's price to be fair in a discounted-cash-flow model, Genpact Limited would have to grow free cash flow by -5.1 % per year for five years (discount rate 8.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.5 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of G use?
Our models discount Genpact Limited at 8.6 %: a base by market capitalisation (mid), damped by beta 0.54, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Genpact Limited that is -5.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.6 %) and the same formula as our fair value.
How much growth has Genpact Limited (G) delivered so far?
Over the past 5 years revenue at Genpact Limited grew +6.5 % a year. The price currently implies free-cash-flow growth of -5.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Genpact Limited (G) growing?
The median revenue growth in the sector is +7.8 % a year. That is the yardstick for the growth priced into Genpact Limited (-5.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Genpact Limited (G)?
The free-cash-flow yield on the price is 10.20 %: that much free cash flow Genpact Limited produces per unit of market value. When it exceeds the discount rate of our models (8.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Genpact Limited (G)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genpact Limited it is $61.02 per share (as of Nov 7, 2026), against a price of $42.27. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Genpact Limited stock overvalued or undervalued in 2026?
As of Nov 7, 2026, G trades below its calculated fair value: price $42.27, fair value $61.02, a gap of about +44% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of G?
No. The price is what the market pays today ($42.27); the fair value is what the company's own numbers justify ($61.02). For Genpact Limited the two are $18.75 per share apart. That gap is exactly why we show both numbers side by side.
How much is Genpact Limited worth?
The market values Genpact Limited at about $7.2B (market capitalisation, as of Nov 7, 2026). Per share that is $42.27; our models calculate a fair value of $61.02 per share.
What do the bullish and bearish scenarios say about G?
Our models span a range for Genpact Limited: cautious scenario $44.40, base $61.02, optimistic $77.63 per share (as of Nov 7, 2026, price $42.27). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of G?
Genpact Limited trades at a price-to-earnings ratio of 12.3 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $61.02 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, 6 of the years ex one-offs: 20.5. Other multiples: PEG 1.2, P/B 2.8, P/S 1.3, EV/EBITDA 8.5.
What is the PEG ratio of G?
The PEG ratio of Genpact Limited is 1.16 (P/E divided by earnings growth, as of Nov 7, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Genpact Limited (G)?
Balance-sheet figures for Genpact Limited (as of Nov 7, 2026): return on equity 22.4%, debt of 0.47 per unit of equity. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
How far is G from its 52-week high?
Genpact Limited trades at $42.27, about 11% below its 52-week high of $47.73 and 55% above the low of $27.35 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $61.02 is for.
Which stocks are comparable to Genpact Limited?
From the same area (Technology) we also value International Business Machines Corporation, Accenture plc, Tata Consultancy Services Limited, Infosys Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genpact Limited stock attractive at the current price?
The data as of Nov 7, 2026: price $42.27, calculated fair value $61.02 (+44%), Quality Score 71/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of G calculated?
We run Genpact Limited through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $61.02 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Genpact Limited currently trades 31% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genpact Limited (G)?
The closing price on Nov 6, 2026 was $42.27. Our model-based fair value is $61.02, about +44% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genpact Limited right now?
The price is below even our cautious bear case ($44.40). The market is more pessimistic than our downside scenario. Solid quality (71/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of Genpact Limited (G) come from?
Earnings per share at Genpact Limited grew +12.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +10.0 %, EBIT margin +1.1 %, tax rate +0.7 %, residual (interest, one-offs) +0.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Genpact Limited
How large is the market capitalisation of Genpact Limited (G)?
The market capitalisation of Genpact Limited is $7.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genpact Limited (G)?
The price-to-sales ratio of Genpact Limited is 1.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genpact Limited (G)?
Earnings per share at Genpact Limited are $3.43 (price ÷ EPS = P/E 12.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Genpact Limited (G)?
The dividend yield of Genpact Limited is 0.4% (payout 5.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Genpact Limited (G)?
The net margin of Genpact Limited is 11.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genpact Limited (G)?
The return on equity (ROE) of Genpact Limited is 22.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genpact Limited (G)?
On an EBIT basis the return on assets of Genpact Limited is 12.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genpact Limited (G)?
The operating margin of Genpact Limited is 15.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genpact Limited (G)?
Revenue at Genpact Limited is growing +7.3% versus a year earlier (3y avg +5.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Genpact Limited (G)?
Earnings per share at Genpact Limited are growing +7.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Genpact Limited (G) carry?
The net debt of Genpact Limited is $911M (fiscal year 2025, ≈ 1.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Genpact Limited in the live analysis
One click puts Genpact Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026